HK1178920A1 - Anti-c4.4a antibodies and uses thereof c4.4a - Google Patents

Anti-c4.4a antibodies and uses thereof c4.4a

Info

Publication number
HK1178920A1
HK1178920A1 HK13106500.5A HK13106500A HK1178920A1 HK 1178920 A1 HK1178920 A1 HK 1178920A1 HK 13106500 A HK13106500 A HK 13106500A HK 1178920 A1 HK1178920 A1 HK 1178920A1
Authority
HK
Hong Kong
Prior art keywords
antibodies
Prior art date
Application number
HK13106500.5A
Other languages
English (en)
Chinese (zh)
Inventor
Lars Linden
Yong-Jiang Cao
Gabriele Leder
Beatrix Stelte-Ludwig
Axel Harrenga
Ricarda Finnern
Frank Dittmer
Anke Mayer-Bartschmid
Juergen Franz
Simone Greven
Jrg Willuda
Jan Tebbe
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of HK1178920A1 publication Critical patent/HK1178920A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
HK13106500.5A 2009-12-09 2013-06-03 Anti-c4.4a antibodies and uses thereof c4.4a HK1178920A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09178474 2009-12-09
EP10170797 2010-07-26
PCT/EP2010/069216 WO2011070088A1 (en) 2009-12-09 2010-12-08 Anti-c4.4a antibodies and uses thereof

Publications (1)

Publication Number Publication Date
HK1178920A1 true HK1178920A1 (en) 2013-09-19

Family

ID=43629588

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13106500.5A HK1178920A1 (en) 2009-12-09 2013-06-03 Anti-c4.4a antibodies and uses thereof c4.4a

Country Status (28)

Country Link
US (2) US20120321619A1 (pl)
EP (2) EP2510012B1 (pl)
JP (3) JP5989544B2 (pl)
KR (1) KR101931820B1 (pl)
CN (1) CN102812047B (pl)
AR (1) AR079340A1 (pl)
AU (1) AU2010329904B2 (pl)
BR (1) BR112012013915A8 (pl)
CA (1) CA2783338A1 (pl)
CY (1) CY1119051T1 (pl)
DK (1) DK2510012T3 (pl)
ES (1) ES2632748T3 (pl)
HK (1) HK1178920A1 (pl)
HR (1) HRP20170973T1 (pl)
HU (1) HUE034847T2 (pl)
IL (1) IL219801A (pl)
IN (1) IN2012DN05175A (pl)
LT (1) LT2510012T (pl)
MX (1) MX2012006593A (pl)
NZ (1) NZ600470A (pl)
PL (1) PL2510012T3 (pl)
PT (1) PT2510012T (pl)
RS (1) RS56161B1 (pl)
RU (1) RU2577977C2 (pl)
SI (1) SI2510012T1 (pl)
TW (1) TWI488642B (pl)
WO (1) WO2011070088A1 (pl)
ZA (1) ZA201203498B (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011158883A1 (ja) * 2010-06-15 2011-12-22 国立大学法人大阪大学 癌予後判定可能な抗体、および癌予後判定方法
US20130122024A1 (en) 2011-04-21 2013-05-16 Bayer Intellectual Property Gmbh New binder-drug conjugates (adcs) and use thereof
JP2014117191A (ja) * 2012-12-13 2014-06-30 Fisheries Research Agency リン酸化中性スフィンゴミエリナーゼ１、抗リン酸化中性スフィンゴミエリナーゼ１抗体、中性スフィンゴミエリナーゼ１変異体、及びそれらの用途
JP2017534251A (ja) * 2014-09-09 2017-11-24 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Ａｇｒ２およびその受容体ｃ４．４ａに対する遮断モノクローナル抗体
WO2016166169A1 (en) * 2015-04-17 2016-10-20 Spring Bioscience Corporation Antibodies, compositions, and immunohistochemistry methods for detecting c4.4a
WO2017096397A1 (en) * 2015-12-04 2017-06-08 The Regents Of The University Of California Novel antibodies for the treatment of cancers
WO2017156280A1 (en) * 2016-03-09 2017-09-14 Viba Therapeutics, Inc. Methods of treating cancer using monoclonal antibodies to agr2 and c4.4a
EP3574019A4 (en) 2017-01-26 2021-03-03 Surrozen, Inc. TISSUE SPECIFIC, WNT SIGNAL REINFORCEMENT MOLECULES AND USES THEREOF
JP7052389B2 (ja) * 2018-02-07 2022-04-12 株式会社三洋物産 遊技機
CA3106967A1 (en) * 2018-07-20 2020-01-23 Duke University Anti-lypd3 car t-cell therapy for the treatment of cancer
MX2021005433A (es) * 2018-11-08 2021-06-15 Univ Kagawa Nat Univ Corp Metodo para producir una composicion que contiene azucar raro y una composicion que contiene el azucar raro.
CN111349164B (zh) * 2018-12-21 2023-05-26 艾比玛特医药科技（上海）有限公司 糖基磷脂酰肌醇锚定糖蛋白（c4.4a）的单克隆抗体及其应用
WO2020257770A1 (en) * 2019-06-21 2020-12-24 Children's National Medical Center Methods and composition for a binding molecule targeting cancer cells expressing ssx2 peptide 41-49 in hla-a*0201 context
WO2023175117A1 (en) 2022-03-16 2023-09-21 Glycotope Gmbh Antibodies against lypd3
WO2023240135A2 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
PT859841E (pt) 1995-08-18 2002-11-29 Morphosys Ag Bibliotecas de proteinas/ (poli) peptidos
DE69710911T2 (de) * 1996-05-31 2002-09-19 Health Research Inc Monoklonale Antikörper gegen Endoglin und ihre Verwendung in der anti-Angiogenese-Therapie
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1220919A2 (en) * 1999-09-29 2002-07-10 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Metastasis-associated antigen c4.4a
AU2002329540A1 (en) * 2001-06-20 2003-01-02 Morphosys Ag Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
MXPA06014065A (es) * 2004-06-01 2007-01-31 Genentech Inc Conjugados de droga-anticuerpo y metodos.
WO2008073312A2 (en) * 2006-12-08 2008-06-19 Attenuon, Llc Urokinase-type plasminogen activator receptor epitope, monoclonal antibodies derived therefrom and methods of use thereof
US20130122024A1 (en) * 2011-04-21 2013-05-16 Bayer Intellectual Property Gmbh New binder-drug conjugates (adcs) and use thereof

Also Published As

Publication number Publication date
EP3144323A2 (en) 2017-03-22
AR079340A1 (es) 2012-01-18
RU2012128343A (ru) 2014-01-20
JP2018019721A (ja) 2018-02-08
CN102812047A (zh) 2012-12-05
EP3144323A3 (en) 2017-05-31
MX2012006593A (es) 2012-06-28
LT2510012T (lt) 2017-07-25
JP2016104820A (ja) 2016-06-09
CY1119051T1 (el) 2018-01-10
ES2632748T3 (es) 2017-09-15
CN102812047B (zh) 2015-08-26
PT2510012T (pt) 2017-07-13
US20170158775A1 (en) 2017-06-08
IL219801A (en) 2016-08-31
SI2510012T1 (sl) 2017-08-31
JP2013513369A (ja) 2013-04-22
IL219801A0 (en) 2012-07-31
RU2577977C2 (ru) 2016-03-20
PL2510012T3 (pl) 2017-09-29
JP5989544B2 (ja) 2016-09-07
ZA201203498B (en) 2015-10-28
EP2510012B1 (en) 2017-04-19
TWI488642B (zh) 2015-06-21
HUE034847T2 (en) 2018-03-28
CA2783338A1 (en) 2011-06-16
KR20120116958A (ko) 2012-10-23
JP6240696B2 (ja) 2017-11-29
TW201134485A (en) 2011-10-16
BR112012013915A8 (pt) 2017-12-26
KR101931820B1 (ko) 2018-12-21
DK2510012T3 (en) 2017-07-31
RS56161B1 (sr) 2017-11-30
IN2012DN05175A (pl) 2015-10-23
NZ600470A (en) 2015-02-27
BR112012013915A2 (pt) 2017-01-10
WO2011070088A1 (en) 2011-06-16
AU2010329904A1 (en) 2012-06-14
AU2010329904B2 (en) 2015-07-09
HRP20170973T1 (hr) 2017-09-22
EP2510012A1 (en) 2012-10-17
US20120321619A1 (en) 2012-12-20

Similar Documents

Publication Publication Date Title
HRP20170973T1 (hr) Anti-c4.4a protutijela i njihova uporaba
HK1199031A1 (en) Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof 2--5--1,2,4-
IL226383A0 (en) Antibodies against ccl20, preparations containing them and their uses
PL2354161T3 (pl) Przeciwciało anty -NR10 i jego zastosowanie
ZA201107486B (en) Anti-tnf-x antibodies and their uses
EP2494062A4 (en) ANTI-GLP-1R ANTIBODIES AND THEIR USES
EP2478110A4 (en) CLASS I ANTI-CEA ANTIBODIES AND USES THEREOF
IL216014A0 (en) Antibodies immunorective with heregulin-her3 complexes, compositions comprising the same and uses thereof
HK1195776A1 (zh) -α 抗-α 抗體及其應用
ZA201002445B (en) Hiv preventive vaccine based on hiv specific antibodies
IL220536A0 (en) Anti - bv8 antibodies and uses thereof
EP2399934A4 (en) NEW MONOCLONAL ANTIBODY AND USE THEREOF
SI2354161T1 (sl) Anti-NR10 protitelo in njegova uporaba
EP2507263A4 (en) ANTI-IGF-IR ANTIBODIES AND ITS USES
IL214527A0 (en) Anti-mst1r antibodies and uses thereof
EP2515903A4 (en) COMPOUNDS, PREPARATION AND USES THEREOF
Ersoj Fletët-Safahat
AP2011005854A0 (en) Novel GP41 antigens.
Stern Why we Worry
GB0906115D0 (en) Antibody and uses thereof
Idriz Konvertimi dhe asimilimi i Dhimmī-ve në Perandorinë Osmane
Iskandar Gerila
Muja Ulqini dhe Tivari: ndërmjet Krishterimit dhe Islamit
Samojlov STVARALAŠTVO MILUTINA MILANKOVIĆA
Ryan New Urbanism Uncovered

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20191208